NCT05683834 2025-11-21
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT05831111 2025-09-30
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT04645147 2025-07-17
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05164094 2025-05-15
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting